Back to top

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

In a report released today, from Roth MKM initiated coverage with a Buy rating on Protagonist Therapeutics and a price target of $72.00. The compan...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Invesco Financial Preferred ETF (PGF)

Protagonist Therapeutics, Inc. (PTGX)